Please login to the form below

Valid News, Market Access Insights, Issue 3

Wherever you are in the world, it’s important to have a holistic view of what’s happening in the market.

Wherever you are in the world, it’s important to have a holistic view of what’s happening in the market. So for Issue 3 of Valid News, we’re discussing developments from across the globe. It’s also important to be able to access the insights, support and advice you need, anytime, anywhere, which is why we’ve launched virtual workshops – making our expertise always accessible. You can find all the information you need on these, and more, inside.

Download the newsletter now for insight into:

  • our predictions for the future of market access
  • the impact of free prescriptions
  • why medicinal products are denied in France
  • how to prepare for reimbursement
  • the vicious cycle of contracting and tendering
  • explaining the price of your product
  • virtual workshops to elevate value, pricing and market access strategies

Download the newsletter now here: https://www.validinsight.com/resource-center/valid-news-market-access-insights-issue-3/

25th October 2019

Share

Company Details

Valid Insight

+44 (0) 20 3750 9833

Contact Website

Address:
152-160 City Road
Kemp House
London
EC1V 2NX
United Kingdom

Latest content on this profile

Webinar: How to develop an optimal value story for your product
This webinar is part of the ongoing expert insights series run by Valid Insight
Valid Insight
Last chance to register - Webinar: How to price a pharmaceutical product during a global economic recession
How can you ensure your product achieves optimal market access during a global economic recession?
Valid Insight
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen.
Valid Insight
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative to alternative treatments for successful market access. In this blog, we summarise the reasons for negative reimbursement decisions in 2017 and discuss common pitfalls manufacturers should avoid.
Valid Insight
Using TRAVELLESS™ to provide tailored pharmaceutical training
In May 2020, Valid Insight were scheduled to travel to Grenoble to deliver the market access modules as part of the Advanced Master’s in Biotechnology & Pharmaceutical Management programme with Grenoble Ecole de Management, a French graduate business school. The course has participants from varied backgrounds, but all from roles within the pharmaceutical industry.
Valid Insight
The vicious circle of pharmaceutical tendering
Pharmaceutical tendering and contracting has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s. In the 1990s, international institutions such as the World Health Organisation and the World Bank endorsed tendering as the preferred procurement process for drugs.
Valid Insight